These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 22445286)

  • 1. Discovery and evaluation of spirocyclic derivatives as antagonists of the neuropeptide Y5 receptor.
    Fichtner M; Lee E; Tomlinson E; Scott D; Cornelius P; Patterson TA; Carpino PA
    Bioorg Med Chem Lett; 2012 Apr; 22(8):2738-43. PubMed ID: 22445286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel orally active NPY Y5 receptor antagonists: Synthesis and structure-activity relationship of spiroindoline class compounds.
    Sakamoto T; Moriya M; Tsuge H; Takahashi T; Haga Y; Nonoshita K; Okamoto O; Takahashi H; Sakuraba A; Hirohashi T; Shibata T; Kanno T; Ito J; Iwaasa H; Gomori A; Ishihara A; Fukuroda T; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Jul; 17(14):5015-26. PubMed ID: 19525116
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aryl urea derivatives of spiropiperidines as NPY Y5 receptor antagonists.
    Takahashi T; Haga Y; Sakamoto T; Moriya M; Okamoto O; Nonoshita K; Shibata T; Suga T; Takahashi H; Hirohashi T; Sakuraba A; Gomori A; Iwaasa H; Ohe T; Ishihara A; Ishii Y; Kanatani A; Fukami T
    Bioorg Med Chem Lett; 2009 Jul; 19(13):3511-6. PubMed ID: 19464889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and evaluation of new arylsulfonamidomethylcyclohexyl derivatives as human neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Moreno A; Pérez S; Galiano S; Juanenea L; Erviti O; Frígola C; Aldana I; Monge A
    Eur J Med Chem; 2004 Jan; 39(1):49-58. PubMed ID: 14987833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of tetrasubstituted imidazolines as potent and selective neuropeptide Y Y5 receptor antagonists: reduced human ether-a-go-go related gene potassium channel binding affinity and potent antiobesity effect.
    Sato N; Ando M; Ishikawa S; Jitsuoka M; Nagai K; Takahashi H; Sakuraba A; Tsuge H; Kitazawa H; Iwaasa H; Mashiko S; Gomori A; Moriya R; Fujino N; Ohe T; Ishihara A; Kanatani A; Fukami T
    J Med Chem; 2009 May; 52(10):3385-96. PubMed ID: 19459652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery and structure-activity relationship of a novel spirocarbamate series of NPY Y5 antagonists.
    Leslie CP; Bentley J; Biagetti M; Contini S; Di Fabio R; Donati D; Genski T; Guery S; Mazzali A; Merlo G; Pizzi DA; Sacco F; Seri C; Tessari M; Zonzini L; Caberlotto L
    Bioorg Med Chem Lett; 2010 Oct; 20(20):6103-7. PubMed ID: 20813523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of trans-N-[1-(2-fluorophenyl)-3-pyrazolyl]-3-oxospiro[6-azaisobenzofuran-1(3H),1'-cyclohexane]-4'-carboxamide, a potent and orally active neuropeptide Y Y5 receptor antagonist.
    Haga Y; Sakamoto T; Shibata T; Nonoshita K; Ishikawa M; Suga T; Takahashi H; Takahashi T; Takahashi H; Ando M; Murai T; Gomori A; Oda Z; Kitazawa H; Mitobe Y; Kanesaka M; Ohe T; Iwaasa H; Ishii Y; Ishihara A; Kanatani A; Fukami T
    Bioorg Med Chem; 2009 Oct; 17(19):6971-82. PubMed ID: 19720539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of novel orally active ureido NPY Y5 receptor antagonists.
    Li G; Stamford AW; Huang Y; Cheng KC; Cook J; Farley C; Gao J; Ghibaudi L; Greenlee WJ; Guzzi M; van Heek M; Hwa JJ; Kelly J; Mullins D; Parker EM; Wainhaus S; Zhang X
    Bioorg Med Chem Lett; 2008 Feb; 18(3):1146-50. PubMed ID: 18160282
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A neuropeptide Y Y5 antagonist selectively ameliorates body weight gain and associated parameters in diet-induced obese mice.
    Ishihara A; Kanatani A; Mashiko S; Tanaka T; Hidaka M; Gomori A; Iwaasa H; Murai N; Egashira S; Murai T; Mitobe Y; Matsushita H; Okamoto O; Sato N; Jitsuoka M; Fukuroda T; Ohe T; Guan X; MacNeil DJ; Van der Ploeg LH; Nishikibe M; Ishii Y; Ihara M; Fukami T
    Proc Natl Acad Sci U S A; 2006 May; 103(18):7154-8. PubMed ID: 16636293
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of a novel Y5 antagonist in obese mice: combination with food restriction or sibutramine.
    Mashiko S; Ishihara A; Iwaasa H; Moriya R; Kitazawa H; Mitobe Y; Ito J; Gomori A; Matsushita H; Takahashi T; MacNeil DJ; Van der Ploeg LH; Fukami T; Kanatani A
    Obesity (Silver Spring); 2008 Jul; 16(7):1510-5. PubMed ID: 18421274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of independent and combined chronic anti-obese effects of NPY Y2 receptor agonist, PYY(3-36), and NPY Y5 receptor antagonist in diet-induced obese mice.
    Moriya R; Mashiko S; Ishihara A; Takahashi T; Murai T; Ito J; Mitobe Y; Oda Z; Iwaasa H; Takehiro F; Kanatani A
    Peptides; 2009 Jul; 30(7):1318-22. PubMed ID: 19394383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis of new benzoxazinone derivatives as neuropeptide Y5 antagonists for the treatment of obesity.
    Torrens A; Mas J; Port A; Castrillo JA; Sanfeliu O; Guitart X; Dordal A; Romero G; Fisas MA; Sánchez E; Hernández E; Pérez P; Pérez R; Buschmann H
    J Med Chem; 2005 Mar; 48(6):2080-92. PubMed ID: 15771450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Obesity and the central nervous system.
    Mifflin SW; Strack A
    J Physiol; 2007 Sep; 583(Pt 2):423. PubMed ID: 17766646
    [No Abstract]   [Full Text] [Related]  

  • 14. An insurmountable NPY Y5 receptor antagonist exhibits superior anti-obesity effects in high-fat diet-induced obese mice.
    Fukasaka Y; Nambu H; Tanioka H; Obata A; Tonomura M; Okuno T; Yukioka H
    Neuropeptides; 2018 Aug; 70():55-63. PubMed ID: 29801968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structure-activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related compounds as neuropeptide Y5 receptor antagonists.
    Norman MH; Chen N; Chen Z; Fotsch C; Hale C; Han N; Hurt R; Jenkins T; Kincaid J; Liu L; Lu Y; Moreno O; Santora VJ; Sonnenberg JD; Karbon W
    J Med Chem; 2000 Nov; 43(22):4288-312. PubMed ID: 11063624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, synthesis, and biological evaluation of substituted 2-cyclohexyl-4-phenyl-1H-imidazoles: potent and selective neuropeptide Y Y5-receptor antagonists.
    Blum CA; Zheng X; De Lombaert S
    J Med Chem; 2004 Apr; 47(9):2318-25. PubMed ID: 15084130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of oxadiazole derivatives with a spirocyclic cyclohexane structure as novel GPR119 agonists.
    Harada K; Mizukami J; Watanabe T; Mori G; Ubukata M; Suwa K; Fukuda S; Negoro T; Sato M; Inaba T
    Bioorg Med Chem Lett; 2019 Aug; 29(16):2100-2106. PubMed ID: 31288965
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
    Erondu N; Gantz I; Musser B; Suryawanshi S; Mallick M; Addy C; Cote J; Bray G; Fujioka K; Bays H; Hollander P; Sanabria-Bohórquez SM; Eng W; Långström B; Hargreaves RJ; Burns HD; Kanatani A; Fukami T; MacNeil DJ; Gottesdiener KM; Amatruda JM; Kaufman KD; Heymsfield SB
    Cell Metab; 2006 Oct; 4(4):275-82. PubMed ID: 17011500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis and evaluation of new hydrazide derivatives as neuropeptide Y Y5 receptor antagonists for the treatment of obesity.
    Juanenea L; Galiano S; Erviti O; Moreno A; Pérez S; Aldana I; Monge A
    Bioorg Med Chem; 2004 Sep; 12(17):4717-23. PubMed ID: 15358298
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The identification of a series of novel, soluble non-peptidic neuropeptide Y Y2 receptor antagonists.
    Lunniss GE; Barnes AA; Barton N; Biagetti M; Bianchi F; Blowers SM; Caberlotto LL; Emmons A; Holmes IP; Montanari D; Norris R; Puckey GV; Walters DJ; Watson SP; Willis J
    Bioorg Med Chem Lett; 2010 Dec; 20(24):7341-4. PubMed ID: 21074426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.